Overview

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma
Phase:
PHASE2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.